Haiqing Isaac Dai

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Artificial Intelligence

Mesenchymal Stem Cells

Top Venues

Clinical and translational science

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ping Hu, Haiqing Isaac Dai, James Bourdage, Dongli Zhou, Ky Trang, Karey Kowalski, Carlo Bello, Jennifer E Hibma, Akash Khandelwal, Kyra Cowan, Jennifer Dong, Karthik Venkatakrishnan, Wei Gao
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma. Clinical and translational science 17 (3) (2024)
Ping Hu, Haiqing Isaac Dai, James Bourdage, Dongli Zhou, Ky Trang, Karey Kowalski, Carlo Bello, Jennifer E Hibma, Akash Khandelwal, Kyra Cowan, Jennifer Dong, Karthik Venkatakrishnan, Wei Gao
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma. Clinical and translational science 17 (3) (2024)
Ping Hu, Haiqing Isaac Dai, James Bourdage, Dongli Zhou, Ky Trang, Karey Kowalski, Carlo Bello, Jennifer E Hibma, Akash Khandelwal, Kyra Cowan, Jennifer Dong, Karthik Venkatakrishnan, Wei Gao
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma. Clinical and translational science 17 (3) (2024)
Ping Hu, Haiqing Isaac Dai, James Bourdage, Dongli Zhou, Ky Trang, Karey Kowalski, Carlo Bello, Jennifer E Hibma, Akash Khandelwal, Kyra Cowan, Jennifer Dong, Karthik Venkatakrishnan, Wei Gao
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma. Clinical and translational science 17 (3) (2024)
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects. Clinical pharmacology and therapeutics 108 (6) (2020)